Chronic Spontaneous Urticaria (CSU) - Epidemiology Forecast - 2032

DelveInsight's 'Chronic Spontaneous Urticaria - Epidemiology Forecast - 2032' report delivers an in-depth understanding of Chronic Spontaneous Urticaria, historical and forecasted epidemiology, as well as the Chronic Spontaneous Urticaria trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.

Chronic Spontaneous Urticaria Disease Understanding:

Urticaria is a common and heterogeneous inflammatory skin disorder with or without associated angioedema. It presents with wheals, angioedema, or both due to activation and degranulation of skin mast cells, followed by the release of histamine and other mediators leading to sensory nerve activation, vasodilatation, plasma extravasation, and cellular recruitment. It is classified as acute or chronic, depending on whether the onset of episodes lasts for less or >6 weeks, respectively.

Chronic urticaria is spontaneous or inducible, lasts >6 weeks, and persists for >1 year. It impacts the quality of life and is linked to psychiatric comorbidities and high healthcare costs, often causing huge socio-economic distress for the patients. In contrast to chronic spontaneous urticaria (CSU), where the cause is unknown, chronic inducible urticaria (CIndU) has definite and subtype-specific triggers that induce signs and symptoms.

The etiology of CSU is yet to be fully established. The exact cause is often unknown, but it may be due to autoimmune reactions wherein the immune system mistakenly targets healthy cells in the skin. Other potential triggers include foods, medications, infections, insect bites, stress, and temperature changes. The prognosis in CSU depends on the comorbid disease causing the urticaria and the patient's response to therapy.

Chronic Spontaneous Urticaria diagnosis

The diagnosis is based on a physical examination and medical history. Additional tests are performed to rule out underlying causes or to identify triggers, such as blood tests, allergy tests, or skin biopsies. Screening tests for thyroid function and anti-thyroid peroxidase and anti-thyroglobulin antibodies are recommended. Positive autologous serum skin test (ASST) and in vitro testing of the patient's serum for the anti-FCeRIa or the anti-IgE autoantibodies by basophil histamine release assay (BHRA) is also recommended.

Some tools have been developed to assess disease activity (e.g., urticaria activity score), disease control (e.g., urticaria control test), and impacts on quality of life (e.g., chronic urticaria quality of life index). Baseline assessments should be performed to help guide treatment decisions and monitor progress. Continued in the report…..

Chronic Spontaneous Urticaria Epidemiology Perspective by DelveInsight

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by diagnosed prevalent cases of chronic urticaria, type-specific cases of chronic urticaria, age-specific cases of chronic spontaneous urticaria, gender-specific cases of chronic spontaneous urticaria, and severity-specific cases of chronic spontaneous urticaria scenario in the 7MM covering the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan from 2019 to 2032.

Chronic Spontaneous Urticaria Detailed Epidemiology Segmentation

• In 2022, the total diagnosed prevalent cases of chronic urticaria were estimated to be approximately 4,154,234 cases in the 7MM.
• Among the 7MM, the United States accounted for nearly 19% of the total diagnosed prevalent cases of chronic urticaria in 2022. These cases are expected to increase further during the study period (2019-2032).
• As per DelveInsight analysis, in the US, there were around 517,258 and 258,629 cases of CSU and CIndU, respectively, in 2022. The cases are expected to rise during the study period.
• In 2022, the total diagnosed prevalent cases of chronic spontaneous urticaria were estimated to be approximately 2,811,068 cases in the 7MM. These cases are expected to increase by 2032 at a CAGR of 0.02% during the study period (2019-2032).
• The age-specific cases of chronic spontaneous urticaria in Germany in 2022 were approximately 30,353, 36,142, 49,454, 53,673, 54,785, and 102,670 in the age groups <18, 18-29, 30-39, 40-49, 50-59, =60 respectively.
• In 2022, in Japan, there were approximately 393,294 cases of chronic spontaneous urticaria in males and 672,543 cases of chronic spontaneous urticaria in females. These gender-specific cases are expected to decrease in Japan by 2032.
• According to estimates based on DelveInsight's epidemiology model of chronic spontaneous urticaria, in 2022, in EU4 and the UK, there were approximately 173,390 cases of mild, 487,997 cases of moderate, and 566,587 cases of severe chronic spontaneous urticaria, which are expected to increase by 2032.

Scope of the Report:

• The report covers a descriptive overview of chronic spontaneous urticaria, explaining its symptoms, grading, pathophysiology, and various diagnostic approaches.
• The report provides insight into the 7MM historical and forecasted patient pool covering the United States, the EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.
• The report assesses the disease risk and burden of chronic spontaneous urticaria.
• The report recognizes the growth opportunities in the 7MM concerning the patient population.
• The report describes the disease epidemiology for the 7MM, diagnosed prevalent cases of chronic urticaria, type-specific cases of chronic spontaneous urticaria, age-specific cases of chronic spontaneous urticaria, gender-specific cases of chronic spontaneous urticaria, and severity-specific cases of chronic spontaneous urticaria.

Report Highlights:

• Ten-year forecast of chronic spontaneous urticaria
• The 7MM coverage
• Diagnosed prevalent cases of chronic urticaria
• Type-specific cases of chronic urticaria
• Age-specific cases of chronic spontaneous urticaria
• Gender-specific cases of chronic spontaneous urticaria
• Severity-specific cases of chronic spontaneous urticaria

Key Questions Answered:

• What are the disease risk and burdens of chronic spontaneous urticaria?
• What is the historical chronic spontaneous urticaria patient pool in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan?
• What would be the forecasted patient pool of chronic spontaneous urticaria at the 7MM level?
• What growth opportunities will be across the 7MM concerning the patient population with chronic spontaneous urticaria?
• Out of the above-mentioned countries, which country would have the highest prevalent population of chronic spontaneous urticaria during the forecast period (2023-2032)?
• At what CAGR is the population expected to grow across the 7MM during the forecast period (2023-2032)?

Reasons to Buy:

The chronic spontaneous urticaria report will allow the user to:

• Develop business strategies by understanding the trends shaping and driving the 7MM chronic spontaneous urticaria epidemiology forecast.
• The chronic spontaneous urticaria epidemiology report and model were written and developed by Master's and PhD level epidemiologists.
• The chronic spontaneous urticaria epidemiology model developed by DelveInsight is easy to navigate, interactive with a dashboard, and epidemiology based on transparent and consistent methodologies. Moreover, the model supports the data presented in the report and showcases disease trends over the Ten-year forecast period using reputable sources.

Key Assessments

• Patient segmentation
• Disease risk and burden
• Risk of disease by the segmentation
• Factors driving growth in a specific patient population

Geographies Covered:

• The United States
• EU4 (Germany, France, Italy, and Spain) and the United Kingdom
• Japan

Study Period: 2019-2032.